SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Tunica Albuginea who wrote (4712)1/17/1998 4:54:00 PM
From: LoLoLoLita  Read Replies (1) of 23519
 
>>By the way , have you analyzed the risks involved in
>>owning Vivus stock? gg.

Of course! Biggest risk for share price right now is delay
in MCA approval of second plant. DR BOND has been emphatic
in assuring us that this will happen in February, and we all
are of course aware that his predictions usually come true.

Even if it happens end-March, and they ship all that overhang
product the last day of Q1, it will be a big boost for the Q1
earnings. So that means that DR BOND can be off by a whole
month and we should still all be "in the money" by summertime.

If anyone calls Nina Ferrari, please try to get as much info
as possible about the status of the MCA review. For example,
what were the specific questions asked by MCA, and what
responses have been given, and when.

David
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News